About Lundbeckfonden Emerge

Who we are

Petriskål test

Lundbeckfonden Emerge is an evergreen investor established by the Lundbeck Foundation in 2012. Our investments cover all therapeutics areas in life science and all stages of development from inception to clinical validation. Since our start in 2012, our portfolio has grown to seven active investments, which comprise companies from discovery to late clinical phases. Based on the 2030 strategy, we expect to grow our investments during the next decade.

Our investment approach is always tailored to the specific project or company in question. Our involvement therefore spans a wide range of potential activities, which ranges from exploratory investments in startup companies to investments in more mature companies in clinical stage. We approach our projects and investments with a hands-on and operational approach as best to lend active help and mentoring as well as on board level. Each project is considered on its own merits and with a focus on building value.

Our team is comprised by industry experts with extensive entrepreneurial, operational, scientific, and business experience from the life-science industry. We focus our work on the Danish biotech-sector but we operate in close dialogue with our strong network of international life science and venture capital investors and are conscious of the need to maintain a strong bridge between Denmark and the global biotech-industry. We leverage our network in the venture capital, pharma, and biotech industry to help entrepreneurs build value for all shareholders. 

Working with us

Our investments typically arise from innovative research in Denmark and we may involve ourselves operationally to help and support researchers and founders in the challenging journey from science to company. This requires a multitude of activities; from detailed analysis of the science, intellectual property, commercial market opportunities, human resources and more. We deploy equity financing or other relevant financing tools.

Our ambition is to identify and work with teams that can solve unmet medical needs with a strong commercial potential. As investors, we want to generate an attractive financial return and strengthen the Danish biotech ecosystem long term. This means translating innovation into business, growth and jobs.

Our interests and investments cover all therapeutic areas within the life-science sector. The starting point for a dialogue with us can be either a commercial project idea based on new scientific insights or a business plan for an already established business looking for new financial investors. We are interested in both.

The first step is for you to share a non-confidential summary of your project idea or business with us. On this basis we may then arrange a meeting where we can learn more about you and discuss your ideas going forward. Continued interest from both sides will then lead to a closer dialogue where we discuss and agree the plan going forward and our level of involvement. Preceding any investment, we will conduct a thorough due diligence analysis of the available data before final commercial deal negotiation.

Please reach out if you are interested in discussing your project or company with Lundbeckfonden Emerge.
You can reach us at
emerge@lundbeckfonden.com

Kontakt

Christian Elling

Managing Partner Lundbeckfonden BioCapital

Mobil

+45 2062 1276